Overview

* Structure Therapeutics ( GPCR ) reports Q3 net loss of $65.7 mln, compared to $34 mln in 2024

* Company maintains strong cash position of $799 mln, funding operations through 2027

* Phase 1 study for oral amylin receptor agonist ACCG-2671 to start by year-end 2025

Outlook

* Structure Therapeutics ( GPCR ) expects topline data from ACCESS studies by year-end 2025

* Company plans to initiate Phase 1 study of ACCG-2671 by year-end 2025

* Company expects cash reserves to fund operations through at least 2027

Result Drivers

* R&D EXPENSES - Increased R&D expenses driven by clinical trial costs and preclinical research for GLP-1R franchise

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$65.71

Income mln

Q3 -$73.79

Income mln

From

Operatio

ns

Q3 $73.79

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Structure Therapeutics Inc ( GPCR ) is $65.00, about 50.4% above its November 5 closing price of $32.21

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)